Table Of Content
Preliminary data may come from models, observational studies or the endpoints of related studies. Some preliminary data should be available to support most of the trial’s design; not only to support the hypothesis but also to support trial feasibility. It is essential to learn as much as possible about the target disease’s epidemiology (e.g. prevalence), and about recruitment and adherence in similar trials.
Code, Data and Media Associated with this Article
Specifically, patients are grouped into strata according to the important factors and then randomized within each stratum. For considerations on other study designs, including adaptive, group sequential and Bayesian designs, see Pallmann et al. (2018), Bhatt and Mehta (2016), Vandemeulebroecke (2008), Lee and Chu (2012), and Berry (2006). For considerations when drafting a statistical analysis plan for clinical trials, see Gamble et al. (2017).
Outline of types of designs for clinical studies
Clinical trial design is a key aspect of the successful conduct of clinical trials. To address this need, in March 2020 we began planning a phase 2 adaptive platform trial, I-SPY COVID (Fig. 1). Given the large number of potential therapeutic approaches being proposed, the study was designed to rapidly evaluate and prioritize promising agents for further phase 3 testing.
Pragmatic Elements: An Introduction to PRECIS-2 - Rethinking Clinical Trials
Pragmatic Elements: An Introduction to PRECIS-2.
Posted: Tue, 26 Sep 2023 16:33:19 GMT [source]
Phase III
On the other hand, retrospective cohort studies identify a population with and without the risk factor/exposure based on past records and then assess if they had developed the disease/outcome at the time of study. Thus, the study design for prospective and retrospective cohort studies are similar as we are comparing populations with and without exposure/risk factor to development of outcome/disease. If risks are very low and the study is easy (and not too expensive) to conduct, a pilot trial can help quantify and better evaluate the benefits, helping optimize them for future trial designs. For instance, a study evaluating the analgesic effects of gabapentin enrolled 24 PLP patients (17). However, pain level differences in the active group (even if over half the participants had a meaningful decrease in pain) did not reach significance compared to placebo. Related to randomization, allocation concealment (which should always be implemented), also protects against selection bias, e.g. such that investigators cannot encourage only patients they think will benefit to enroll in the trial.
Control Arm Options in Controlled Trials
In the remainder of this paper, we frame our guidelines around these phases in the design process of a clinical trial. Throughout the paper, we provide references for the interested reader to find further details and explanations of concepts and terms. What are the lessons learned from this trial experience that may have important implications for future pandemics and/or clinical trials in a similar treatment space? First, there is a unique niche for phase 2 clinical trials that can rapidly evaluate repurposed or novel agents for which preliminary safety data exist, but fewer data are available in support of efficacy than would be advisable in a standard phase 3 study.
6 Selection of a control group
For example, toxic epidermal necrolysis, where clinical outcomes in cyclosporine treated patients can be compared with historical controls treated in the same center with IVIg in the past. In the treatment of some diseases, it may take a very long time to observe the definitive endpoint (e.g., death). A surrogate endpoint is a measure that is predictive of the clinical event but takes a shorter time to observe. The definitive endpoint often measures clinical benefit whereas the surrogate endpoint tracks the progress or extent of disease. Surrogate endpoints could also be used when the clinical end-point is too expensive or difficult to measure, or not ethical to measure. Other examples of subjective endpoints include depression, anxiety, or sleep quality.
The researcher needs to perform a benefit/risk assessment when choosing a study design. Trial results can never be guaranteed but it may be reasonable to expect benefit based on previous studies; this benefit may occur at the individual or group level, with subsets of patients improving dramatically and others not at all. A critical element of a non-inferiority design is the non-inferiority margin the design will exclude. There are no specific rules on what threshold would warrant a conclusion of “non-inferiority,” though some regulatory agencies have provided guidance in some situations, and margins vary widely across endpoints, patient populations, and trials [39,40,41,42,43,44].
Trials participants must be treated with the utmost respect, and that begins with careful attention to informed consent. In this module, you’ll learn about the personnel, documents, terminology, and practices that go into planning and implementing ethically sound informed consent procedures within your trial. To the Editor — It is difficult to forget the chaos, anxiety and heightened urgency of early 2020, when COVID-19 became a global pandemic. Infections around the world were skyrocketing, while clinicians faced tremendous uncertainty over how to treat this devastating new infection. Hundreds of different therapeutic approaches were proposed, many of which had a relatively weak link to the pathophysiology of COVID-19, our understanding of which was rapidly evolving. Without data to guide clinicians, tens of thousands of patients received a wide range of untested therapies.
Cohort studies are study designs that compare two groups, such as the subjects with exposure/risk factor to the subjects without exposure/risk factor, for differences in incidence of outcome/disease. Most often, cohort study designs are used to study outcome(s) from a single exposure/risk factor. Thus, cohort studies can also be hypothesis testing studies and can infer and interpret a causal relationship between an exposure and a proposed outcome, but cannot establish it (Figure 4). One way to see the importance of this problem is by analyzing the attrition rate from early to late phases. Attrition means the drop in the number of drugs that make it to market compared to those studied in preclinical and clinical trials.
The investigator needs to be cautious and conservative in his/her choices given the risk of losing time and resources in an invalid or valid negative trial. Progressive trial phases require more preliminary data to increase the potential benefits and reduce the risks of the trial. Poorly designed trials often lead to inconclusive or negative results, usually at significant human and financial cost. Clinical trials can only be ethically justified when the potential benefits of a new intervention (whether it is a drug, device, surgery, etc.) for the target population outweighs its risks (4,5). Benefits are “the positive results of a given treatment for an individual or a population (i.e. efficacy, convenience, or even quality of life)”, while risks are “the unfavorable negative results (adverse outcomes) of a given treatment for an individual or a population” (6). The expected risk/benefit ratio will depend on the trial phase and supporting data, as we discuss below.
However, when historical data are very reliable, well documented and other disease and treatment conditions have not changed since the historical trial was conducted, then they can be considered. Historical controls have become common in device trials when placebo-controls are not a viable option. Historical controls can be helpful in interpreting the results from trials for which placebo controls are not ethical (e.g., oncology trials).
Several of the challenges of clinical trial design discussed here are applicable to PLP research. Each design choice has implications for the quality and validity of your results. This course provides you and your team with essential skills to evaluate options, make good design choices, and implement them within your trial. You’ll learn to control for bias, randomize participants, mask treatments and outcomes, identify errors, develop and test hypotheses, and define appropriate outcomes. Finally, a trial without participants is no trial at all, so you’ll learn the guiding principles and develop the essential skills to ethically and conscientiously recruit, obtain consent from, and retain trial participants.
For traditional randomized designs, this depends on three primary factors that the research team must decide together – effect size, (statistical) power, and statistical significance level. Effect size refers to the minimum treatment effect that one hopes to detect in the study. Power refers to the likelihood of detecting an effect when in fact there is an effect of a priori specified size.
No comments:
Post a Comment